Agios Pharmaceuticals (AGIO) Competitors $36.06 +0.71 (+1.99%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$36.06 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AGIO vs. BBIO, ROIV, RVMD, ELAN, LEGN, GRFS, TLX, TGTX, LNTH, and NUVLShould you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include BridgeBio Pharma (BBIO), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Elanco Animal Health (ELAN), Legend Biotech (LEGN), Grifols (GRFS), Telix Pharmaceuticals (TLX), TG Therapeutics (TGTX), Lantheus (LNTH), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Agios Pharmaceuticals vs. Its Competitors BridgeBio Pharma Roivant Sciences Revolution Medicines Elanco Animal Health Legend Biotech Grifols Telix Pharmaceuticals TG Therapeutics Lantheus Nuvalent Agios Pharmaceuticals (NASDAQ:AGIO) and BridgeBio Pharma (NASDAQ:BBIO) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability. Do insiders & institutionals have more ownership in AGIO or BBIO? 99.9% of BridgeBio Pharma shares are owned by institutional investors. 4.3% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility and risk, AGIO or BBIO? Agios Pharmaceuticals has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Does the media favor AGIO or BBIO? In the previous week, BridgeBio Pharma had 17 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 24 mentions for BridgeBio Pharma and 7 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.54 beat BridgeBio Pharma's score of 0.31 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 7 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts prefer AGIO or BBIO? Agios Pharmaceuticals presently has a consensus price target of $58.60, suggesting a potential upside of 62.53%. BridgeBio Pharma has a consensus price target of $58.85, suggesting a potential upside of 34.64%. Given Agios Pharmaceuticals' higher probable upside, research analysts plainly believe Agios Pharmaceuticals is more favorable than BridgeBio Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agios Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71BridgeBio Pharma 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.93 Is AGIO or BBIO more profitable? Agios Pharmaceuticals has a net margin of 1,798.26% compared to BridgeBio Pharma's net margin of -524.25%. BridgeBio Pharma's return on equity of 0.00% beat Agios Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Agios Pharmaceuticals1,798.26% -2.75% -2.52% BridgeBio Pharma -524.25%N/A -94.43% Which has higher earnings and valuation, AGIO or BBIO? Agios Pharmaceuticals has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAgios Pharmaceuticals$36.50M57.21$673.72M$11.243.21BridgeBio Pharma$221.90M37.40-$535.76M-$3.53-12.38 SummaryAgios Pharmaceuticals and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks. Get Agios Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AGIO vs. The Competition Export to ExcelMetricAgios PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.09B$2.91B$5.53B$9.05BDividend YieldN/A2.44%5.24%4.03%P/E Ratio3.2121.5627.5220.22Price / Sales57.21281.76421.02118.64Price / CashN/A42.7336.8958.07Price / Book1.337.518.045.67Net Income$673.72M-$55.05M$3.18B$249.13M7 Day Performance7.72%4.61%2.90%3.28%1 Month Performance7.37%4.72%3.70%5.55%1 Year Performance-15.46%5.92%36.15%21.12% Agios Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AGIOAgios Pharmaceuticals4.1161 of 5 stars$36.06+2.0%$58.60+62.5%-14.2%$2.09B$36.50M3.21390Insider TradeBBIOBridgeBio Pharma4.7029 of 5 stars$42.17+1.1%$56.67+34.4%+74.8%$7.92B$221.90M-11.95400News CoverageInsider TradeAnalyst RevisionROIVRoivant Sciences1.554 of 5 stars$11.50+0.4%$17.50+52.2%+3.5%$7.78B$29.05M-46.00860RVMDRevolution Medicines4.5889 of 5 stars$40.04+1.0%$67.08+67.5%+0.2%$7.39B$11.58M-10.01250Analyst RevisionELANElanco Animal Health2.2364 of 5 stars$13.36-0.7%$15.17+13.5%+3.6%$6.68B$4.44B18.059,000News CoverageAnalyst ForecastLEGNLegend Biotech2.9607 of 5 stars$33.85-0.4%$76.20+125.1%-23.0%$6.25B$627.24M-57.372,609Analyst ForecastGRFSGrifols4.0538 of 5 stars$8.37-4.6%$10.30+23.1%+36.7%$6.03B$7.81B7.1523,822TLXTelix PharmaceuticalsN/A$16.39-4.4%$22.00+34.2%N/A$5.80B$516.72M0.00N/ANews CoverageAnalyst ForecastGap DownHigh Trading VolumeTGTXTG Therapeutics3.2899 of 5 stars$36.56+1.5%$40.80+11.6%+98.0%$5.72B$329M152.33290LNTHLantheus4.4622 of 5 stars$80.81+2.0%$130.50+61.5%-0.4%$5.48B$1.53B22.96700NUVLNuvalent3.7151 of 5 stars$75.98+1.3%$115.50+52.0%+11.5%$5.39BN/A-17.3140Insider Trade Related Companies and Tools Related Companies BridgeBio Pharma Alternatives Roivant Sciences Alternatives Revolution Medicines Alternatives Elanco Animal Health Alternatives Legend Biotech Alternatives Grifols Alternatives Telix Pharmaceuticals Alternatives TG Therapeutics Alternatives Lantheus Alternatives Nuvalent Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AGIO) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Agios Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AGIO Stock Alerts